Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of single-dose CRG-B191 in neovascular age-related macular degeneration
CTR20254412Phase 2Active
- Sponsor
- Keruike Pharma
- Start
- Mar 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CRG-B191 in exudative macular degeneration, sponsored by Keruike Pharma. Started Mar 2026; status: active.
02
Drugs
CRG-B191
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20254412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254412.